FHC
ACAD icon

First Horizon Corporation’s Acadia Pharmaceuticals ACAD Stock Holding History

First Horizon Corporation’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6
Closed – – 1053
2021
Q1 		$0 Hold
6
– – ﹤0.01% 1035
2020
Q4 		$0 Hold
6
– – ﹤0.01% 1027
2020
Q3 		$0 Buy
+6
New +$259 ﹤0.01% 1002

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

First Horizon Corporation's ACAD Position: Q2 2021 in Review

First Horizon Corporation sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 6 shares.

First Horizon Corporation first reported a position in ACAD in Q3 2020 and held it in 3 quarters. The position peaked at $0 in Q1 2021. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

  • First Horizon Corporation reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • First Horizon Corporation sold 6 Acadia Pharmaceuticals shares in Q2 2021.
  • First Horizon Corporation first reported a position in Acadia Pharmaceuticals in Q3 2020 and held it in 3 quarters.
  • First Horizon Corporation's Acadia Pharmaceuticals position peaked at $0 in Q1 2021.
  • 245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on First Horizon Corporation's 13F filing for Q2 2021, filed 9 Aug 2021.